Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/4858
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTufan, Ahmet Çevik-
dc.contributor.authorSatıroğlu-Tufan, Naciye Lale-
dc.date.accessioned2019-08-16T11:38:04Z
dc.date.available2019-08-16T11:38:04Z
dc.date.issued2005-
dc.identifier.issn1568-0096-
dc.identifier.urihttps://hdl.handle.net/11499/4858-
dc.identifier.urihttps://doi.org/10.2174/1568009054064624-
dc.description.abstractAngiogenesis, the formation of new blood vessels, is essential for tumor growth, progression and metastasis. The development of agents that target tumor vasculature is ultimately dependent on the availability of appropriate preclinical screening assays. The chorioallantoic membrane (CAM) assay is well established and widely used as a model to examine angiogenesis, and anti-angiogenesis. This review 1) summarizes the currently used angiogenesis assays and the importance of CAM model among them; 2) summarizes the current knowledge about the development and structure of the CAM's capillary bed; 3) reports findings regarding the role played by molecular signaling pathways in angiogenesis process; 4) discusses the use, advantages and limitations of the CAM as a model for studying tumor angiogenesis and invasiveness, as well as development of angiogenic and/or anti-angiogenic agents; 5) discusses the importance of standardization of the major methodologies for all aspects of the use of the CAM in angiogenesis-related studies; 6) and finally, summarizes major findings regarding the agents developed by the use of CAM model in the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. © 2005 Bentham Science Publishers Ltd.en_US
dc.language.isoenen_US
dc.relation.ispartofCurrent Cancer Drug Targetsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject1,4 phenylenebis(methylene)selenocyanateen_US
dc.subjectacetylsalicylic aciden_US
dc.subjectalpha cyclodextrinen_US
dc.subjectalpha thymosin peptideen_US
dc.subjectamilorideen_US
dc.subjectangiogenesis inhibitoren_US
dc.subjectangiogenin antibodyen_US
dc.subjectangiopoietin receptoren_US
dc.subjectangiostatinen_US
dc.subjectangiotensinogenen_US
dc.subjectangiotensinogen derivativeen_US
dc.subjectanthracycline derivativeen_US
dc.subjectapomorphineen_US
dc.subjectarylsulfatase inhibitoren_US
dc.subjectbasic fibroblast growth factor antibodyen_US
dc.subjectbeta cyclodextrinen_US
dc.subjectbleomycinen_US
dc.subjectcarbohydrate derivativeen_US
dc.subjectcell adhesion molecule antagonisten_US
dc.subjectcortisoneen_US
dc.subjectcyclosporinen_US
dc.subjectcytokineen_US
dc.subjectdoxorubicinen_US
dc.subjectendostatinen_US
dc.subjectfenretinideen_US
dc.subjectfibroblast growth factoren_US
dc.subjectfibroblast growth factor 2en_US
dc.subjectgm 1474en_US
dc.subjectgoniodomin Aen_US
dc.subjectheparan sulfateen_US
dc.subjectheparanase inhibitoren_US
dc.subjectheparinen_US
dc.subjecthomocysteineen_US
dc.subjecthyaluronic acid binding proteinen_US
dc.subjectindinaviren_US
dc.subjectindole derivativeen_US
dc.subjectinterleukin 2en_US
dc.subjectkininogenen_US
dc.subjectkininogen derivativeen_US
dc.subjectkininostaten_US
dc.subjectmatrix metalloproteinase inhibitoren_US
dc.subjectmetastatinen_US
dc.subjectmicrosomal aminopeptidase inhibitoren_US
dc.subjectmitogen activated protein kinase p38en_US
dc.subjectmonoclonal antibodyen_US
dc.subjectmotuporanineen_US
dc.subjectnitric oxideen_US
dc.subjectornithine decarboxylase inhibitoren_US
dc.subjectpentosan polysulfateen_US
dc.subjectpeptide derivativeen_US
dc.subjectplatelet derived growth factoren_US
dc.subjectprotamineen_US
dc.subjectprotamine sulfateen_US
dc.subjectproteasome inhibitoren_US
dc.subjectprotein tyrosine kinase inhibitoren_US
dc.subjectprothrombinen_US
dc.subjectpurine derivativeen_US
dc.subjectretinoiden_US
dc.subjectruthenium red derivativeen_US
dc.subjectsaquinaviren_US
dc.subjectscatter factoren_US
dc.subjectsomatostatinen_US
dc.subjectsomatostatin derivativeen_US
dc.subjectspironolactoneen_US
dc.subjectsqualamineen_US
dc.subjectsteroiden_US
dc.subjectstromelysinen_US
dc.subjectsulindacen_US
dc.subjectsuraminen_US
dc.subjectsuramin derivativeen_US
dc.subjecttamoxifenen_US
dc.subjectthalidomideen_US
dc.subjectthrombocyte factor 4en_US
dc.subjectthymidine phosphorylase inhibitoren_US
dc.subjecttitanocene dichlorideen_US
dc.subjecttransforming growth factor alphaen_US
dc.subjecttransforming growth factor betaen_US
dc.subjectu 995en_US
dc.subjectunclassified drugen_US
dc.subjectvasculotropinen_US
dc.subjectvasculotropin antibodyen_US
dc.subjectvasculotropin diphtheria toxin conjugateen_US
dc.subjectvasculotropin receptor 2en_US
dc.subjectangiogenesisen_US
dc.subjectapoptosisen_US
dc.subjectassayen_US
dc.subjectcancer invasionen_US
dc.subjectcapillaryen_US
dc.subjectcell cultureen_US
dc.subjectcell growthen_US
dc.subjectcell migrationen_US
dc.subjectcell proliferationen_US
dc.subjectcell viabilityen_US
dc.subjectchemokinesisen_US
dc.subjectchick embryoen_US
dc.subjectchorioallantoisen_US
dc.subjectcost effectiveness analysisen_US
dc.subjectDNA synthesisen_US
dc.subjectdrug mechanismen_US
dc.subjectembryo developmenten_US
dc.subjectendothelium cellen_US
dc.subjectfetus membraneen_US
dc.subjectin vivo studyen_US
dc.subjectmesodermen_US
dc.subjectmetastasisen_US
dc.subjectmodelen_US
dc.subjectmorphometricsen_US
dc.subjectnonhumanen_US
dc.subjectorgan cultureen_US
dc.subjectprotein familyen_US
dc.subjectprotein functionen_US
dc.subjectreviewen_US
dc.subjectscoring systemen_US
dc.subjectstandardizationen_US
dc.subjecttumor growthen_US
dc.subjecttumor vascularizationen_US
dc.subjectvalidation processen_US
dc.subjectAngiogenesis Inhibitorsen_US
dc.subjectAnimalsen_US
dc.subjectChick Embryoen_US
dc.subjectChorioallantoic Membraneen_US
dc.subjectDrug Evaluation, Preclinicalen_US
dc.subjectHumansen_US
dc.subjectModels, Biologicalen_US
dc.subjectNeoplasm Invasivenessen_US
dc.subjectNeoplasmsen_US
dc.subjectNeovascularization, Pathologicen_US
dc.titleThe chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agentsen_US
dc.typeReviewen_US
dc.identifier.volume5en_US
dc.identifier.issue4en_US
dc.identifier.startpage249
dc.identifier.startpage249en_US
dc.identifier.endpage266en_US
dc.authorid0000-0001-9399-0960-
dc.identifier.doi10.2174/1568009054064624-
dc.relation.publicationcategoryDiğeren_US
dc.identifier.pmid15975046en_US
dc.identifier.scopus2-s2.0-21344456550en_US
dc.identifier.wosWOS:000230100100002en_US
dc.identifier.scopusqualityQ1-
dc.ownerPamukkale_University-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeReview-
crisitem.author.dept14.03. Basic Medical Sciences-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

115
checked on Sep 16, 2024

WEB OF SCIENCETM
Citations

100
checked on Sep 8, 2024

Page view(s)

44
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.